Upgrade to SI Premium - Free Trial

Biogen (BIIB) PT Lowered to $215 at BofA Securities

July 21, 2026 5:31 AM
BofA Securities analyst Jason Zemansky lowered the price target on Biogen (NASDAQ: BIIB) to $215.00 (from $217.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change